Moderna and Merck say a made-to-order mRNA treatment has passed a late-stage melanoma trial — a first for cancer medicine. Unlike a Covid vaccine made identically for millions, each dose is designed from the genetic fingerprint of a patient’s tumour. Here’s what has been achieved, how it works — and what we still don’t know
